#USA #New York #Levi & Korsinsky #Baxter Int'l #BAX

Levi & Korsinsky Issues Notice to Baxter International Investors

Levi & Korsinsky, LLP has recently brought attention to investors regarding a class action lawsuit against Baxter International, Inc. (NYSE: BAX). This legal action aims to reclaim losses suffered by shareholders due to alleged securities fraud occurring from February 23, 2022, to July 30, 2025. The firm encourages affected investors to consider asserting their rights in this matter, with a crucial deadline approaching on December 15, 2025, for those wishing to be appointed as lead plaintiffs.

Class Action Overview

The scope of the lawsuit focuses on Baxter International's recently launched product, the Novum LVP. The complaint alleges that this medical device is fraught with systemic defects leading to severe malfunctions. These defects reportedly cause critical errors such as underinfusion, overinfusion, and even total failure to deliver necessary fluids to patients, which consequently poses risks of serious injury or fatality.

The allegations extend to include claims that Baxter was aware of numerous malfunctions linked with the Novum LVP and had received reports of injuries and deaths attributed to such defects. Critics argue that the company's attempts to alert clients about these issues were insufficient and that the underlying design flaws persisted, continuing to jeopardize patients' safety.

The repercussions of these claims suggest a heightened likelihood that Baxter would have to withdraw existing products from circulation and halt any further sales of the Novum LVP—a move that could significantly impact the company's financial stability. Consequently, prior claims made by Baxter regarding the safety and effectiveness of the Novum LVPs are seen as materially misleading and false.

Next Steps for Investors

For those who suffered a loss during the specified timeframe, it is essential to act before the December 15, 2025 deadline. Interested parties can request to be appointed as lead plaintiff, but participation in potential recovery does not necessitate this role.

Levi & Korsinsky stresses that there is no financial obligation for class members wishing to partake in this suit. Investors may be entitled to compensation without requiring any upfront costs or fees.

Why Choose Levi & Korsinsky?

Over the past two decades, Levi & Korsinsky has distinguished itself in the realm of securities litigation by securing hundreds of millions in settlements for shareholders. Recognized consistently by ISS Securities Class Action Services, the firm has maintained a reputation as one of the top firms in this specialized field, equipped with over 70 professionals dedicated exclusively to serving their clients.

For those desiring further information on this lawsuit or who wish to register their claim, they may contact Joseph E. Levi, Esq. at 212-363-7500 or through email at [email protected].

Investors are also encouraged to visit their website for more information and additional resources related to the lawsuit and the lead plaintiff process.

Contact Information

Name: Joseph E. Levi, Esq.
Address: 33 Whitehall Street, 17th Floor, New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500
Website: zlk.com

As the lead plaintiff deadline approaches, Baxter investors are urged to stay informed and take necessary actions to safeguard their investments.